Research Analysts Offer Predictions for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($1.12) for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th.

Eledon Pharmaceuticals Stock Performance

Shares of Eledon Pharmaceuticals stock opened at $4.25 on Wednesday. Eledon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.54. The firm’s 50-day simple moving average is $4.28 and its 200-day simple moving average is $3.45. The firm has a market cap of $253.90 million, a PE ratio of -2.11 and a beta of 0.79.

Institutional Investors Weigh In On Eledon Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in shares of Eledon Pharmaceuticals during the second quarter valued at approximately $1,584,000. Inspire Investing LLC bought a new position in Eledon Pharmaceuticals during the 4th quarter worth $802,000. Renaissance Technologies LLC increased its position in Eledon Pharmaceuticals by 57.1% in the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock worth $361,000 after buying an additional 49,704 shares during the period. Armistice Capital LLC lifted its stake in Eledon Pharmaceuticals by 1.7% in the second quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock valued at $6,167,000 after buying an additional 39,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Eledon Pharmaceuticals by 9.7% during the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock valued at $942,000 after acquiring an additional 33,569 shares during the period. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).